Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Prepaid Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Prepaid Assets for 16 consecutive years, with $158664.0 as the latest value for Q1 2026.

  • Quarterly Prepaid Assets fell 23.48% to $158664.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $158664.0 through Jan 2026, down 23.48% year-over-year, with the annual reading at $223759.0 for FY2025, 13.87% down from the prior year.
  • Prepaid Assets for Q1 2026 was $158664.0 at PharmaCyte Biotech, down from $503147.0 in the prior quarter.
  • The five-year high for Prepaid Assets was $503147.0 in Q4 2025, with the low at $28148.0 in Q3 2022.
  • Average Prepaid Assets over 5 years is $227992.4, with a median of $223759.0 recorded in 2025.
  • Peak annual rise in Prepaid Assets hit 317.41% in 2022, while the deepest fall reached 94.87% in 2022.
  • Over 5 years, Prepaid Assets stood at $256808.0 in 2022, then grew by 25.85% to $323189.0 in 2023, then skyrocketed by 52.61% to $493213.0 in 2024, then grew by 2.01% to $503147.0 in 2025, then crashed by 68.47% to $158664.0 in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $158664.0, $503147.0, and $238180.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.